Author

C. Blaj

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Assay:metagenomics· 1 Assay:proteomics· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

A. de Castro· 1 shared C. J. Nicolai· 1 shared C. Moore· 1 shared C. O. Ndubaku· 1 shared D. H. Raulet· 1 shared E. Mugarza· 1 shared E. Quintana· 1 shared G. Snyder· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. de Castro

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Combining RASG12C(ON) inhibitor with SHP2 inhibition sensitises immune excluded lung tumours to immune checkpoint blockade: a strategy for turning cold tumours hot

P. Anastasiou, C. Moore, S. Rana, A. de Castro, M. Tomaschko, J. Boumelha, E. Mugarza, C. Blaj, S. de Carne Trecesson, R. Goldstone, J. Smith, E. Quintana, M. Molina-Arcas, J. Downward

This paper shows that combining RASG12C(ON) and SHP2 inhibitors can make cold lung tumors responsive to immune checkpoint blockade by altering the tumor microenvironment and enhancing anti-tumor immunity.

bioRxiv · Jan 15, 2024Cancer Biology

Powerful synergistic effects of a STING agonist and an IL-2 superkine in cancer immunotherapy against MHC I-deficient and MHC I+ tumors

N. K. Wolf, C. Blaj, L. Picton, G. Snyder, L. Zhang, C. J. Nicolai, C. O. Ndubaku, S. M. McWhirter, K. C. Garcia, D. H. Raulet

The paper combines a STING agonist and an IL-2 superkine to enhance cancer immunotherapy, showing efficacy against both MHC I-deficient and MHC I+ tumors.

bioRxiv · Nov 2, 2021 · PreprintImmunology